Literature DB >> 24445571

Host and viral determinants of the outcome of exposure to HCV infection genotype 4: a large longitudinal study.

Sanaa M Kamal1, Samar K Kassim2, Amany I Ahmed1, Sara Mahmoud1, Khaled A Bahnasy3, Tamer A Hafez4, Ibrahiem A Aziz5, Iman F Fathelbab6, Hoda M Mansour6.   

Abstract

OBJECTIVES: The objective of this study was to characterize the factors that influence the outcome of exposure to hepatitis C virus (HCV) genotype 4 (HCV-G4) and the course of recent infection.
METHODS: In this longitudinal study, we prospectively assessed the clinical, genetic, virological, and immunological parameters and retrospectively determined single-nucleotide polymorphisms at interleukin-28B (IL-28B) rs12979860 in a well-characterized large cohort recently exposed to HCV-G4.
RESULTS: A total of 136 subjects with acute HCV (new viremia, seroconversion, and HCV-specific T-cell responses) were identified. Forty-eight subjects (35%) had spontaneous viral clearance and 88 subjects developed chronic HCV of which 42 subjects were treated with pegylated interferon monotherapy, with a sustained virologic response (SVR) rate of 88%. Twenty-six subjects developed HCV-specific T-cell immune responses without detectable viremia or seroconversion. IL-28B-CC (odds ratio (OR) 14.22; P<0.0001), multispecific T-cell responses (OR=11.66; P<0.0001), >300 IU/l alanine aminotransferase (ALT) decline within 4 weeks (OR=6.83; P<0.0001), jaundice (OR=3.54; P=0.001), female gender (OR=2.39; P=0.007), and >2.5 log10 HCV-RNA drop within 8 weeks (OR=2.48; P=0.016) were independently associated with spontaneous clearance. ALT normalization and undetectable HCV-RNA predicted SVR. Exposed apparently uninfected participants had a higher frequency of IL-28B-CC than patients with unresolved acute HCV (P<0.001). IL-28B-CC was associated with multispecific T-cell response (r(2)=0.0.835; P<0.001).
CONCLUSIONS: IL-28B-CC genotype, multispecific HCV T-cell responses, rapid decline in ALT, and viral load predict spontaneous clearance and response to acute HCV-G 4 therapy. IL-28B-CC genotype correlates with developing early multispecific T-cell responses. These findings have important implications for predicting the outcome of HCV exposure and acute infection and identifying patients likely to benefit from therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24445571     DOI: 10.1038/ajg.2013.427

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  6 in total

1.  IL-28B genetic variation, gender, age, jaundice, hepatitis C virus genotype, and hepatitis B virus and HIV co-infection in spontaneous clearance of hepatitis C virus.

Authors:  Sergii V Fedorchenko; Anna Klimenko; Tetyana Martynovich; Olga Liashok; Vitaliy Yanchenko
Journal:  Turk J Gastroenterol       Date:  2019-05       Impact factor: 1.852

Review 2.  Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents.

Authors:  Sanaa M Kamal
Journal:  Hepat Med       Date:  2014-06-24

3.  The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study.

Authors:  Heidar Sharafi; Seyed Moayed Alavian; Bita Behnava; Ali Pouryasin; Maryam Keshvari
Journal:  Hepat Mon       Date:  2014-10-01       Impact factor: 0.660

4.  Favourable IFNL3 genotypes are associated with spontaneous clearance and are differentially distributed in Aboriginals in Canadian HIV-hepatitis C co-infected individuals.

Authors:  Nasheed Moqueet; Claire Infante-Rivard; Robert W Platt; Jim Young; Curtis Cooper; Mark Hull; Sharon Walmsley; Marina B Klein
Journal:  Int J Mol Sci       Date:  2015-03-20       Impact factor: 5.923

5.  The Course of Hepatitis C Infection and Response to Anti-viral Therapy in Patients with Thalassemia major and Hepatitis C Infection: A Longitudinal, Prospective Study.

Authors:  Sanaa Kamal; Sara Abdelhakam; Dalia Ghoraba; Mohamed Amer Mohsen; Ahmed Abdel Salam; Hoda Hassan; Leila Nabeigh
Journal:  Mediterr J Hematol Infect Dis       Date:  2019-11-01       Impact factor: 2.576

6.  Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.

Authors:  Juan Macías; Luis F López-Cortés; Francisco Téllez; Eva Recio; Guillermo Ojeda-Burgos; Maria José Ríos; Antonio Rivero-Juárez; Marcial Delgado; Juan A Pineda
Journal:  PLoS One       Date:  2015-12-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.